Compare BKTI & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BKTI | BNTC |
|---|---|---|
| Founded | 1997 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 326.9M | 360.7M |
| IPO Year | 2000 | 2020 |
| Metric | BKTI | BNTC |
|---|---|---|
| Price | $83.74 | $12.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $74.00 | $27.67 |
| AVG Volume (30 Days) | 37.6K | ★ 134.0K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 52.89 | ★ 80.94 |
| EPS | ★ 0.69 | N/A |
| Revenue | ★ $74,094,000.00 | N/A |
| Revenue This Year | $6.57 | N/A |
| Revenue Next Year | $15.00 | N/A |
| P/E Ratio | $119.27 | ★ N/A |
| Revenue Growth | ★ 45.42 | N/A |
| 52 Week Low | $36.17 | $9.85 |
| 52 Week High | $104.55 | $16.76 |
| Indicator | BKTI | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 54.77 | 57.44 |
| Support Level | $76.11 | $11.40 |
| Resistance Level | $85.90 | $13.40 |
| Average True Range (ATR) | 3.14 | 0.87 |
| MACD | 0.50 | 0.19 |
| Stochastic Oscillator | 86.81 | 59.58 |
BK Technologies Corp is a holding company that, through BK Technologies, Inc., its operating subsidiary, provides public safety-grade communications products and services designed to make first responders safer and more efficient. All operating activities described herein are undertaken by its operating subsidiary. The Company has one reportable segment - Land Mobile Radio (LMR) Products and Solutions. The LMR segment provides radio devices that are hand-held (portable) or installed in vehicles (mobile) and operate on private radio systems that are P25 compliant. The Company derives revenue in North America and manages the business activities on a consolidated basis.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.